Dacart development halted based on Phase III results

Dacart development halted based on Phase III results

GSK and MMV recently received data from two Phase III clinical trials assessing use of the artemisinin-based combination therapy Dacart, a fixed-dose combination of chlorproguanil, dapsone and artesunate, currently in clinical development.

On the basis of data received, GSK and MMV have decided to terminate further development of Dacart. GSK has also commenced a product recall process at pharmacy level in Kenya, for Lapdap, this being the only market with recent sales of the product.